



Match Overview



1	Crossref 111 words Glatz, T., P. Bronsert, M. Schäfer, B. Kulemann, G. Marjanovic, O. Sick, U.T. Hopt, K. Zirlik, F. Makowiec, and J. Ho	2%
2	Crossref 89 words Torben Glatz, Birte Kulemann, Jasmina Kuvendjiska, Stefan Fichtner-Feigl, Jens Hoeppner. "Short-term and long-t	2%
3	Internet 71 words crawled on 15-Feb-2020 link.springer.com	2%
4	Internet 68 words crawled on 02-Jun-2020 ar.iijournals.org	1%
5	Internet 50 words crawled on 15-May-2020 www.oncotarget.com	1%
6	Crossref 49 words Koen P. Rovers, Checca Bakkers, Geert A. A. M. Simkens, Jacobus W. A. Burger et al. "Perioperative systemic ther	1%
7	Internet 45 words crawled on 29-Aug-2017 pure.uva.nl	1%
8	Internet 29 words crawled on 14-Mar-2020 www.mdpi.com	1%

11

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 51689

Manuscript Type: ORIGINAL ARTICLE

Retrospective Cohort Study

Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer

Spiegelberg J *et al.* HIPEC treatment in peritoneal-metastasized CRC

Julia Spiegelberg, Hannes Neeff, Philipp Holzner, Mira Runkel, Stefan Fichtner-Feigl, Torben Glatz

Abstract

BACKGROUND

Cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) improves patient survival in colorectal cancer (CRC) with peritoneal carcinomatosis (PC). Commonly used cytotoxic agents include mitomycin C (MMC) and oxaliplatin. With studies reporting varying results, the evidence for the choice of the HIPEC agent and uniform procedure protocols is limited.

AIM

To evaluate therapeutic benefits and complications of CRS + MMC *vs* oxaliplatin



Comparison of hyperthermic intraperitoneal chemotherapy reg



ALL

IMAGES

VIDEOS

8,640 Results

Any time ▾

[Perioperative intraperitoneal chemotherapy for peritoneal ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1481500>

In summary, this review focused on the **perioperative intraperitoneal chemotherapy** currently used for the **treatment of peritoneal surface malignancy** at the Washington **Cancer** Institute. There is a need to standardize the **treatment regimens** and consider incorporating **perioperative intraperitoneal chemotherapy** not only in the management of biopsy proven carcinomatosis, but also in the **treatment** ...

Cited by: 18**Author:** Tristan D Yan, Oswald A Stuart, Dal Yo...**Publish Year:** 2006

[Comparison of two bidirectional hyperthermic ...](#)

https://ascopubs.org/doi/abs/10.1200/jco.2014.32.3_suppl.628

Jan 31, 2017 · 628. Background: Cytoreductive surgery (CRS) and **hyperthermic intraperitoneal chemotherapy** (HIPEC) became part of many national and international **treatment** guidelines as an additive therapeutic option for selected patients with **colorectal** peritoneal metastasis. Multiple HIPEC **regimens** are used regarding cytotoxic agents, concentration, perfusion time and other ...

Author: Gabriel Glockzin, Michael Gerken, ...**Publish Year:** 2014

[Treatment of peritoneal surface malignancies with ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900847>

Jun 09, 2016 · The combination of cytoreductive surgery (crs) and intraoperative **hyperthermic intraperitoneal chemotherapy** (hipec) has successfully been used as locoregional **treatment** for selected patients with ptc from gastric, **colorectal**, and ovarian **cancer**; with mesothelioma; and with pseudomyxoma peritonei.

Cited by: 24**Author:** J. Spiliotis, E. Halkia, E. de Bree**Publish Year:** 2016



Comparison of hyperthermic intraperitoneal chemothera



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

8,650 Results

Any time ▾

[Comparison of two bidirectional hyperthermic ...](#)

https://ascopubs.org/doi/abs/10.1200/jco.2014.32.3_suppl.628

Jan 31, 2017 · 628. Background: Cytoreductive surgery (CRS) and **hyperthermic intraperitoneal chemotherapy** (HIPEC) became part of many national and international **treatment** guidelines as an additive therapeutic option for selected patients with **colorectal** peritoneal metastasis. Multiple HIPEC **regimens** are used regarding cytotoxic agents, concentration, perfusion time and other parameters and ...

Author: Gabriel Glockzin, Michael Gerken, Sv... **Publish Year:** 2014

[Treatment of peritoneal surface malignancies with ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900847>

Jun 09, 2016 · The combination of cytoreductive surgery (crs) and intraoperative **hyperthermic intraperitoneal chemotherapy** (hipec) has successfully been used as locoregional **treatment** for selected patients with ptc from gastric, **colorectal**, and ovarian **cancer**, with mesothelioma, and with pseudomyxoma peritonei.

Cited by: 24 **Author:** J. Spiliotis, E. Halkia, E. de Bree

Publish Year: 2016

[Metastatic Colorectal Cancer: Survival Comparison of ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083005>

The liver is the most common metastatic site of **colorectal cancer**. 1,2 Hepatic metastases (HM) is present in 25 % of patients at the time of diagnosis, 3–6 and 35–55 % of patients will develop HM after primary **colorectal** resection 6–8 and over half of **colorectal cancer** patients will develop HM during their lifetime. 9 In patients with resectable HM, median survival (OS) between 30 and 74 ...

Cited by: 15 **Author:** Aaron U. Blackham, Gregory B. Russell, ...


Publish Year: 2014

[Cytoreductive surgery and hyperthermic intraperitoneal ...](#)

<https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.25116>

Sixty-seven consecutive patients underwent cytoreductive surgery combined with **hyperthermic intraperitoneal** chemoperfusion procedure and systemic **chemotherapy** for metastatic **colorectal cancer**. The control group was selected by a review of the institutional multihospital **cancer** registry and

Hyperthermic intraperitoneal chemotherapy



Intraperitoneal hyperthermic chemoperfusion is a type of hyperthermia therapy used in combination with surgery in the treatment of advanced abdominal cancers. In this procedure, warmed anti-cancer medications are infused and circulated in the peritoneal cavity for a short period of time. The chemotherapeutic agents generally infused during IPHC are mitomycin-C and cisplatin.

 Wikipedia

Data from: Wikipedia

[Suggest an edit](#)